Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis
Advanced Science · 2024
DOI: 10.1002/advs.202401394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Zaigang Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Mitochondria, Energy Metabolism. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar, Zhejiang Qianjiang Talent Plan.
Themen: Depression
Abstract (Originalsprache)
Currently, the typical combination therapy of programmed death ligand‐1 (PD‐L1) antibodies with radiotherapy (RT) still exhibits impaired immunogenic antitumor response in clinical due to lessened DNA damage and acquired immune tolerance via the upregulation of some other immune checkpoint inhibitors. Apart from this, such combination therapy may raise the occurrence rate of radiation‐induced lung fibrosis (RIPF) due to enhanced systemic inflammation, leading to the ultimate death of cancer patients (average survival time of about 3 years). Therefore, it is newly revealed that mitochondria energy metabolism regulation can be used as a novel effective PD‐L1 and transforming growth factor‐β (TGF‐β) dual‐downregulation method. Following this, IR‐TAM is prepared by conjugating mitochondria‐targeted heptamethine cyanine dye IR‐68 with oxidative phosphorylation (OXPHOS) inhibitor Tamoxifen (TAM), which then self‐assembled with albumin (Alb) to form IR‐TAM@Alb nanoparticles. By doing this, tumor‐targeting IR‐TAM@Alb nanoparticle effectively reversed tumor hypoxia and depressed PD‐L1 and TGF‐β expression to sensitize RT. Meanwhile, due to the capacity of heptamethine cyanine dye in targeting RIPF and the function of TAM in depressing TGF‐β, IR‐TAM@Alb also ameliorated fibrosis development induced by RT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.
- Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
- Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
- Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
- Zhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, 325001, China.
ORCID-Profile: Jianliang Shen
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar
- Zhejiang Qianjiang Talent Plan
- Wenzhou Medical University
Zitieren
APA
Zhou, Z., Jiang, X., Yi, L., Li, C., Wang, H., Xiong, W., Li, Z., & Shen, J. (2024). Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis. Advanced Science. https://doi.org/10.1002/advs.202401394
Vancouver
Zhou Z, Jiang X, Yi L, Li C, Wang H, Xiong W, et al. Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis. Advanced Science. 2024. doi:10.1002/advs.202401394
BibTeX
@article{Zhou2024,
author = {Zhou, Zaigang and Jiang, Xin and Yi, Lei and Li, Cheng and Wang, Haoxiang and Xiong, Wei and Li, Zhipeng and Shen, Jianliang},
title = {Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202401394}
}
EUVIMED